Applications

1526 – Somatic tumour gene testing for the diagnosis of diffuse large B cell lymphoma, multiple myeloma and non-Hodgkin lymphoma subtypes

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

New MBS item

Service or technology in this application

The characterisation of: rearrangements in BCL2, BC16, MYC genes for detection of cases of 'double-hit' diffuse large B cell lymphoma, which require more intensive chemotherapy in view of the more aggressive nature of the lymphoma; copy number changes or mutations for the diagnosis and classification of neoplasms or the detection of minimal residual disease of patients with plasma cell myeloma; and histological diagnosis and classification for rare subtypes of non-hodgkin lymphoma.

Type: Investigative

Medical condition this application addresses

Diffuse large B cell lymphoma; copy number abberations and / or mutations fo the diagnosis and classification of plasma cell myeloma; and rare sub-types of non-hodgkin lymphoma that respond poorly to conventional chemotherapy.

Application documents

Application form

Consultation survey

Public summary document

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: 12 to 13 April 2018
  • ESC meeting: -
  • MSAC meeting: 1 to 2 August 2019